Clinical trials: Immunization; Infection
GARDASIL Vaccination
Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series
Planned Parenthood Federation of America's (PPFA) Medical Affairs Division will conduct a prospective, cluster randomized trial to determine which factors influence the acquisition of the second and third human papillomavirus…
- Trial name
- NCT01343485
- Testing
- Computer reminder system
- Where
- 9 sites in United States
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Planned Parenthood Federation of America
Pneumococcal Infections, Pneumococcal Conjugate Vaccine
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.
- Trial name
- NCT03574389
- Testing
- 13vPnC, Hib
- Where
- 2 sites in China
- Volunteers
- 936 people, healthy volunteers welcome
- Sponsor
- Pfizer
Toxic Shock Syndrome
Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Toxic Shock Syndrome (TSS) is a severe condition with high morbidity and mortality from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02814708
- Testing
- rTSST-1v
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Neisseria Meningitidis, Haemophilus Influenzae Type b
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants
The purpose of this Phase II study is to evaluate the feasibility of GSK Biologicals' GSK2197870A vaccine co-administered with Wyeth-Lederle's Prevenar™ when given in healthy infants as a three-dose primary vaccination course at…
- Trial name
- NCT00871338
- Testing
- GSK2197870A, Prevenar™, Menitorix™
- Where
- 5 sites in United Kingdom
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B Vaccine
Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.
The purpose of this study is to assess the persistence of immunity to hepatitis B in children who received three consecutive doses of HBV vaccine (EngerixTM-B) in infancy.
- Trial name
- NCT00519649
- Testing
- Engerix™-B Kinder
- Where
- 35 sites in Germany
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Tetanus
Evaluation of Boostrix™10 Years After Previous Booster Vaccination
The purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a dTpa (Boostrix™ vaccine) booster dose given 10 years after the previous vaccination with dTpa in GSK 263855/029 study.
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria
- Trial name
- NCT01147900
- Testing
- Boostrix™, Boostrix™-US formulation
- Where
- 3 sites in Belgium
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid19
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and…
- Trial name
- NCT04732468
- Testing
- hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Chronic Hepatitis B
Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg
Background: The HBsAg clearance rate in interferon-treated responders is significantly higher than that in lamivudine-treated responders, implying immune control is the key to HBsAg clearance.
- Trial name
- NCT01817725
- Testing
- HBV vaccine (Engerix B)
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Chang Gung Memorial Hospital
Influenza
Higher Dose Intradermal H5 Vaccine
This study will compare the influenza A/H5N1 virus vaccine given by injection in the muscle versus injection in the skin in healthy adults.
- Trial name
- NCT00439335
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US
This C3 project, Community network-driven COVID-19 testing of vulnerable populations in the Central US, will implement and evaluate a COVID-19 testing and vaccination approach that combines an evidence-based Social Network…
- Trial name
- C3 (NCT04743908)
- Testing
- Social Network Strategy + COVID-19 messaging
- Where
- United States
- Volunteers
- 1,328 people, healthy volunteers welcome
- Sponsor
- University of Chicago
HIV-1-infection
Therapeutic Vaccination in Treated HIV Disease
The central premise of our program is that durable control of HIV in the absence of antiretroviral therapy ("remission") will require the generation of de novo potent and sustained HIV-specific CD8+ cell responses that target…
- Trial name
- NCT03606213
- Testing
- PENNVAX-GP, INO-6145, INO-9012
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Steven Deeks
Infections, Meningococcal
Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations
This is Phase IV, Open label, Multicenter study. Subject's parents and/or legal guardian will be provided information about the trial. If interested and if eligible, they will then be asked to provide signed informed consent.
- Trial name
- NCT02446691
- Testing
- MenACWY
- Where
- 6 sites in South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
This study was aimed to explore safety and immunogenicity of two formulations of a Meningococcal B Vaccine when administered to healthy infants.
- Trial name
- NCT00381615
- Testing
- rMenB, rMenB+OMV, DTaP-Hib-IPV
- Where
- 3 sites in United Kingdom
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Health Care Utilization, Vaccine Preventable Disease
Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination
Our objective is to determine the effectiveness of varied outreach methods to children age 12-17 years old who are due for a well child check visit and don't have one scheduled in the next 45 days on the outcomes of appointment…
- Trial name
- NCT04904744
- Testing
- Low tailored message, No message, Low tailored message plus COVID-19 vaccine message
- Where
- United States
- Volunteers
- 1,235 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Influenza, Respiratory Tract Infections
Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- RCT 2
This trial is taking place in Los Angeles, CA among patients from primary care practices within the UCLA Health System. Despite the Advisory Committee on Immunization Practices (ACIP) recommendation in 2010 that all people above…
- Trial name
- NCT04110314
- Testing
- Portal Reminders for Influenza Vaccination: Gain-framed, Portal Reminders for Influenza Vaccination: Loss-framed, Pre-commitment prompt
- Where
- United States
- Volunteers
- 430,636 people
- Sponsor
- University of California, Los Angeles
COVID-19, Vaccinations
COVID-19 Testing and Vaccination Among Spanish Speakers
Latinx communities are disproportionately affected by the COVID-19 pandemic, with Spanish-speaking Latinx communities carrying even heavier burdens of infection, hospitalization, and mortality.
- Trial name
- NCT05302908
- Testing
- NuestraSaludSegura
- Where
- United States
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
COVID-19 Vaccines, Telemedicine
Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool
This study will determine the effectiveness of a vaccine communication mobile health app on parental decisions to vaccinate their children against coronavirus disease 2019 (COVID-19).
- Conditions
- COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
- Trial name
- MoVeUP (NCT05386355)
- Testing
- COVID-19 Vaccine Uptake App, General Health App
- Where
- 15 sites in United States
- Volunteers
- 1,934 people, healthy volunteers welcome
- Sponsor
- IDeA States Pediatric Clinical Trials Network
Meningococcal Disease
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered to subjects from 2 to 17 years of age with increased risk of meningococcal disease because either of primary or secondary complement…
- Trial name
- NCT02141516
- Testing
- rMenB+OMV
- Where
- 20 sites in Italy, Poland and 3 more
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Novartis
Chronic Kidney Diseases, COVID-19
COVID-19 Vaccine Boosters in Patients With CKD
This study is a 12-month, four-arm parallel-group randomized control trial of Pfizer-BioNTech versus MODERNA COVID-19 (Corona Virus disease 2019)vaccine boosters in chronic kidney disease and dialysis patients with poor humoral…
- Trial name
- BOOST KIDNEY (NCT05022329)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine, MODERNA SARS-CoV-2 Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 273 people
- Sponsor
- Sunnybrook Health Sciences Centre
Infections, Streptococcal
Booster and Catch-up Vaccination With Vaccine GSK1024850A
The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of pneumococcal vaccine GSK1024850A administered either at 9-18 months or 15-18 months of age in children primed in primary…
- Trial name
- NCT01030822
- Testing
- Pneumococcal vaccine GSK1024850A
- Where
- 4 sites in India
- Volunteers
- 282 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline